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Shaping the Immune Response
Outline
1) Targeted Synthetic Vaccine Particles (tSVP)
2) SEL-068 – Anti-nicotine vaccine for smoking 
cessation
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Need for new vaccine 
technology















• Autoimmune diseases and 
allergies
• Other chronic diseases   
(e.g. Alzheimer’s disease, 
cardiovascular disease, 
smoking cessation)
Rational Design of targeted Synthetic Vaccine 
Particles (tSVP)
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Nanoparticles Enable Targeted Delivery of 
Immunological Instructions to the Lymph Node


































Advantages of  synthetic tSVP production :
• Scalability
• Stable and Reproducible











• High Batch consistency• Nanoparticle Formation Vessel for 
10 g scale (~10,000 doses)





support Ph 1 trial
tSVP-Encapsulated Adjuvant  is Targeted to 
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Time after inoculation (hrs)


















Time after inoculation (hrs)














NP-OVA + admixed adjuvant 




























•tSVP encapsulation of TLR agonist minimizes systemic cytokine secretion 
Time after injection (hrs)













Time after inoculation (hrs)
















































Percent Adjuvant Release, 37 C
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Universal T-Help Antigen to Boost Response 






















Human PBMC recall response

























Recall response to peptide D observed in 50 of 50 human donors
Small Molecule Antigen* Viral Peptide Antigen*
tSVP Induction of Robust Antibody 




































tSVP Induction of In vivo CTL Responses
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Efficacy and Memory in E.G7 Tumor Model
Therapeutic Dosing Regimen Survivors re-challenged with tumor 
2-3 months later
100
tSVP-immunized long term survivors
tSVP
Saline
Time after tumor inoculation (days)























Time after tumor inoculation (days)





















80 (n = 8)
Non-immunized, tumor-naïve mice 
(n = 5)


















1) Targeted Synthetic Vaccine Particles (tSVP)
2) SEL-068 – Anti-nicotine vaccine for smoking 
cessation
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High prevalence with worldwide smoking population >1B
• 46 million adult smokers in USA – 70% desire to quit (CDC)
• Smoking costs the US $97.6 billion/yr in direct healthcare costs
• 50% of smokers live in BRIC countries
High remaining unmet medical need
Smoking Cessation
• 12 months abstinence rates for current treatment just over 20%
• High relapse risks
Smoking cessation is a worldwide priority for health care providers
• Fast track status for smoking cessation products in the US
• Favorable health economics for smoking cessation products (costs per 
year of life saved) 




specific antibodies that 
bind free nicotine and 
prevent it from crossing 
the blood-brain barrier
Nicotine Vaccine for Smoking Cessation 







NicVax - Nabi (Phase 2)**




Nic002 – Cytos (Phase 2)*








Prior Clinical Studies Validate the Vaccine 




Two independent studies indicate that an effective vaccine for 
smoking cessation can be achieved if antibody titers can be 
increased across a greater percentage of the population







































































































Anti-Nicotine Antibody vs Nicotine AUC
Anti-Nicotine IgG vs Nicotine AUC
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•R&D and Tox Scale
• d0, d14, d28















• R&D Scale 
•d0, d28, d56






















































• d1, d29, d57
• Antibody titers at d85
• Tox scale =P1 scale 



















• Specificity determined by competition ELISA to immobilized poly L-lysine-nicotine






γ-Aminobutyric acid (GABA) <1
Summary
tSVP Platform
• Self-assembling, biocompatible nanoparticles
• Directed delivery of TLR agonists to lymph node
• Universal T cell help peptide
• High antibody titers to poorly immunogenic antigens
• Efficient in vivo induction of CTL activity
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• Antigen-specific immune tolerance
SEL-068 Anti-nicotine vaccine
• Dose-dependent anti-nicotine response
• High titers in mice and two species of non-human primates
• Long term persistance of titers
• GLP tox study in NHP shows no evidence of systemic toxicities




• Selecta begins operations Fall, 2008
• Nicotine program initiated 2009
• >100 formulations made and tested 2009-2010
• Clinical Candidate selected Q4 2010





• GLP Tox complete, no systemic findings Aug, 2011
• GMP supplies released Aug, 2011
• Phase 1  Clinical trial initiated Nov, 2011
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< 3 years
Selecta self-assembling, synthetic nanoparticle platform 
enables rapid iterative optimization of development 
candidates and scale up to GMP
